🌍·3h agodiscoveryTier 3 · Aggregated media
Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026
Publisher
b
businesswire.com
Global
This page provides publisher metadata, and related coverage to support discovery before sending readers to the attributed publisher through Google News.
Open via Google NewsAt a glance
- Publisher
- businesswire.com
- Region
- Global
- Scope
- discovery
- Published
- September 30, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
This record currently routes through Google News. Confirm important claims against the publisher or a primary record.
Source: businesswire.com
Scope: discovery
Evidence: Tier 3 · Aggregated media
Related coverage
More related coverage
Spherical Insights/3h ago
Germany's Pharma Industry Enters a New Investment Phase as Biotech and Innovation Gain Momentum: Expert View by Spherical Insights
Moomoo/4h ago
U.S. Pharmaceutical stocks, with MRK as a notable example, offer greater upside potential than AI stocks whose long-term prospects remain uncertain.
FoodBev Media/4h ago
Biotech Open Platform inaugurates €20m industrial biotechnology facility in France
CommonWealth Beacon/4h ago